Provided by Tiger Trade Technology Pte. Ltd.

Viatris Inc.

17.49
-0.0500-0.29%
Pre-market: 17.610.1213+0.69%09:13 EDT
Volume:7.54M
Turnover:132.65M
Market Cap:20.10B
PE:-49.36
High:17.82
Open:17.52
Low:17.41
Close:17.54
52wk High:18.43
52wk Low:9.69
Shares:1.15B
Float Shares:1.14B
Volume Ratio:0.91
T/O Rate:0.66%
Dividend:0.48
Dividend Rate:2.74%
EPS(TTM):-0.3543
EPS(LYR):-3.0024
ROE:-2.75%
ROA:2.67%
PB:1.41
PE(LYR):-5.83

Loading ...

Australia's Tga: Supply Constraints Affecting Creon Units Due to an Unexpected Global Increase in Demand

THOMSON REUTERS
·
Jun 11

Australia's Tga: Viatris Will Continue to Receive Regular Supplies of All Strengths of Creon in Australia; Availability May Be Limited

THOMSON REUTERS
·
Jun 11

Viatris Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Jun 10

Noveris Health Sciences appoints Geoff Griffiths as strategic advisor

Reuters
·
Jun 09

Viatris Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
Jun 05

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Viatris (VTRS), Medtronic (MDT) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jun 04

Salesforce says Viatris selects Agentforce Life Sciences as global customer engagement platform

Reuters
·
Jun 02

Viatris Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
Jun 02

Viatris Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
May 29

Argus Raises Viatris Price Target to $18 From $15

MT Newswires Live
·
May 28

Viatris Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
May 27

Viatris Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
May 23

Viatris Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
May 21

Viatris Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
May 20

Viatris Is Maintained at Overweight by Barclays

Dow Jones
·
May 19

Barclays Adjusts Price Target on Viatris to $22 From $17, Maintains Overweight Rating

MT Newswires Live
·
May 19

Viatris price target raised to $22 from $17 at Barclays

TIPRANKS
·
May 19

Barclays Remains a Buy on Viatris (VTRS)

TIPRANKS
·
May 19

FDA accepts Viatris fast-acting meloxicam NDA for acute pain review

Reuters
·
May 18

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

THOMSON REUTERS
·
May 18